DLG5 suppresses breast cancer stem cell‐like characteristics to restore tamoxifen sensitivity by inhibiting TAZ expression. Issue 1 (18th November 2018)

• Record Type: Journal Article
• Authors: Liu, Jie; Li, Juan; Li, Pingping; Jiang, Yina; Chen, He; Wang, Ruiqi; Cao, Fang; Liu, Peijun
• Is Part Of: Journal of cellular and molecular medicine. Volume 23:Issue 1(2019)
• Page Start: 512
• Page End: 521
• Publication Date: 2018-11-18
• Subjects: DLG5 -- stemness -- tamoxifen resistance -- TAZ; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.13954
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Tamoxifen (TAM) is a primary drug for treatment of estrogen receptor positive breast cancer. However, TAM resistance remains a serious threat to breast cancer patients and may be attributed to increased stemness of breast cancer. Here, we show that discs large homolog 5 (DLG5) expression is down‐regulated in TAM‐resistant breast cancer and cells. DLG5 silencing decreased the sensitivity to TAM and increased the frequency and stemness of CD44 + /CD24 − breast cancer stem cells (BCSCs) and TAZ, a transducer of the Hippo pathway, expression in MCF7 cells while DLG5 overexpression had opposite effects. TAZ silencing restored the sensitivity to TAM and reduced the frequency and stemness in TAM‐resistant breast cancer cells. Taken together, our data indicate that down‐regulated DLG5 expression increases the stemness of breast cancer cells by enhancing TAZ expression, contributing to TAM resistance in breast cancer.